Back to results
US 2010/0303887 A1Published application
DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
OwnerNicolas G. Bazaninventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerNicolas G. Bazaninventor
Estimating the term…
The combination of pigment epithelium-derived factor (PEDF) and docosahexaenoic acid (DHA) has been discovered to act synergistically to enhance cell survival and decrease apoptosis in retinal pigment epithelial (RPE) cells. PEDF and DHA synergistically protected RPE cells by confronted with oxidative stress by blocking apoptotic cell death and increasing the synthesis of the important mediator neuroprotectin D 1. Administering a composition comprising PEDF and DHA will halt or slow down the initiation and progression of macular degeneration, retinitis pigmentosa and retinal degeneration. In addition, the topical application of the combination of PEDF and DHA was found to promote cornea nerve regeneration after refractive surgery, and thus this combination could be used to prevent the complications of refractive surgery and certain diseases, e.g., neurotrophic keratitis due to Herpes virus.
A sterile medical composition comprising pigment epithelium-derived factor (PEDF) and docosahexaenoic acid (DHA).
An implantable cell culture device, the device comprising a semipermeable membrane permitting the diffusion of pigment epithelium-derived factor (PEDF) and docosahexaenoic acid therethrough;
A composition comprising a mixture of an effective amount of epithelium-derived factor, an effective amount of docosahexaenoic acid, and a pharmaceutically acceptable carrier;
Dependencies are inferred from the claim text.